The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan

BACKGROUND: The Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT) is a trial to determine the clinical efficacy and safety of omalizumab for children with severe atopic eczema. This article describes the detailed statistical analysis plan for the ADAPT as an update to the published protocol and is...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Tao, Chan, Susan, Lack, Gideon, Cro, Suzie, Cornelius, Victoria R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Update
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442690/
https://www.ncbi.nlm.nih.gov/pubmed/28535776
http://dx.doi.org/10.1186/s13063-017-1976-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442690/
https://www.ncbi.nlm.nih.gov/pubmed/28535776
http://dx.doi.org/10.1186/s13063-017-1976-6

Ejemplares similares